Published in:
01-06-2021 | Hepatitis A | Original Article
Hepatology Consultants Often Disagree on Etiology of Abnormal Liver Biochemistries in COVID-19 but Agree on Management
Published in: Digestive Diseases and Sciences | Issue 6/2021
Login to get accessAbstract
Background
Coronavirus disease 2019 (COVID-19) is associated with elevated liver biochemistries in approximately half of hospitalized patients, with many possible etiologies.
Aim
To assess agreement on the etiology of abnormal liver biochemistries and diagnostic recommendations in COVID-19.
Methods
Twenty hepatology consultations were reviewed by three senior hepatologists who provided a differential diagnosis and diagnostic recommendations. Kappa agreement on the primary etiology was calculated.
Results
Kappa agreement between hepatologists on the primary etiology of elevated liver biochemistries was 0.10 (p = 0.03). Agreement was greater around drug-induced liver injury 0.51 (p < 0.0001) and SARS-CoV-2-related liver injury 0.17 (p = 0.03). Serial liver biochemistries were recommended in all consultations over other evaluations.
Conclusion
In COVID-19, elevated liver biochemistries present a diagnostic challenge and can often be monitored conservatively.